Goldman Sachs’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Goldman Sachs’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-50,000	Closed	-$153K	–	6982
2016 Q4	$153K	Hold	50,000	–	–	﹤0.01%	5939
2016 Q3	$232K	Hold	50,000	–	–	﹤0.01%	5698
2016 Q2	$290K	Hold	50,000	–	–	﹤0.01%	5360
2016 Q1	$303K	Sell	50,000 -1,319,400	-96%	-$7.92M	﹤0.01%	5259
2015 Q4	$12.5M	Buy	1,369,400 +50,000	+4%	+$385K	﹤0.01%	2082
2015 Q3	$7.44M	Sell	1,319,400 -2,560,600	-66%	-$21.1M	﹤0.01%	2514
2015 Q2	$43M	Hold	3,880,000	–	–	0.01%	1218
2015 Q1	$60.8M	Sell	3,880,000 -549,200	-12%	-$8.5M	0.02%	956
2014 Q4	$67.4M	Buy	4,429,200 +480,000	+12%	+$5.83M	0.02%	896
2014 Q3	$42.6M	Hold	3,949,200	–	–	0.01%	1191
2014 Q2	$60.3M	Hold	3,949,200	–	–	0.02%	965
2014 Q1	$71.4M	Buy	3,949,200 +935,200	+31%	+$18M	0.02%	809
2013 Q4	$41.9M	Sell	3,014,000 -948,000	-24%	-$10.9M	0.01%	1177
2013 Q3	$41.6M	Hold	3,962,000	–	–	0.02%	1089
2013 Q2	$30.9M	Buy	+3,962,000	New	+$34.6M	0.01%	1216

Other funds holding SGMO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Goldman Sachs's SGMO Position: Q1 2026 in Review

Goldman Sachs increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 98% in Q1 2026, buying an estimated $74.3K and bringing the position to 377,287 shares worth $93.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6221.

Goldman Sachs first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.7M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

Goldman Sachs held 377,287 shares of SANGAMO THERAPEUTICS INC worth $93.2K as of Q1 2026.
Goldman Sachs bought 186,642 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $74.3K.
SANGAMO THERAPEUTICS INC made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6221 holding.
Goldman Sachs first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's SANGAMO THERAPEUTICS INC position peaked at $38.7M in Q4 2020.
112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.